MAPT and Alzheimer disease: For instance, the PET ligand [18F]MK-6240, which has already been validated in AD, is a new generation tau ligand with high sensitivity for NFTs and negligible off-target binding (224), which makes it ideal for defining the extent of tau pathology in HD brains and investigating its relationship with cognitive profile.